NASDAQ: ARVNArvinas Inc Stock
$34.72+0.43 (+1.25%)
Updated Apr 19, 2024
ARVN Price
$34.72
Fair Value Price
-$17.52
Market Cap
$2.36B
52 Week Low
$13.57
52 Week High
$53.08
P/E
-5.24x
P/B
3.58x
P/S
29.1x
PEG
N/A
Dividend Yield
N/A
Revenue
$78.50M
Earnings
-$367.30M
Gross Margin
100%
Operating Margin
-466.75%
Profit Margin
-467.9%
Debt to Equity
0.98
Operating Cash Flow
-$348M
Beta
1.25
Next Earnings
May 3, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ARVN Overview
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ARVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARVN ($34.72) is overvalued by 298.17% relative to our estimate of its Fair Value price of -$17.52 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ARVN ($34.72) is not significantly undervalued (298.17%) relative to our estimate of its Fair Value price of -$17.52 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ARVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARVN due diligence checks available for Premium users.
Be the first to know about important ARVN news, forecast changes, insider trades & much more!
ARVN News
Valuation
ARVN fair value
Fair Value of ARVN stock based on Discounted Cash Flow (DCF)
Price
$34.72
Fair Value
-$17.52
Undervalued by
298.17%
ARVN ($34.72) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARVN ($34.72) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ARVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.24x
Industry
15.81x
Market
40.51x
ARVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.58x
Industry
5.74x
ARVN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ARVN's financial health
Profit margin
Revenue
-$43.1M
Net Income
-$154.8M
Profit Margin
359.2%
ARVN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ARVN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$644.6M
Debt to equity
0.98
ARVN's short-term assets ($1.28B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARVN's short-term assets ($1.28B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARVN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ARVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$83.1M
Investing
-$53.7M
Financing
$334.8M
ARVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ARVN vs Biotech Stocks
Arvinas Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.